Pfizer Gets Interchangeable Designation for Humira Biosimilar

Pfizer announced that the FDA has designated Abrilada (adalimumab-afzb) as an interchangeable biosimilar to Humira (adalimumab), giving pharmacists the ability to substitute it for Humira without intervention from the prescribing clinician.
Source: Drug Industry Daily